Dutch medicine expenditure remains stable

“The new key figures from the NZa show that Dutch expenditure on expensive medicines remains stable,” says Mark Kramer, chairman of the Association of Innovative Medicines (VIG), adding: “That is good news from a social perspective.”

Expenditure on expensive medicines fell from 2.67 billion euros ($2.9 billion) in 2021 to €2.53 billion in 2022. This is evident from the 'Key figures for intramural expensive medicines' , which the NZa published last week. The Dutch Healthcare Authority (NZa) defines 'expensive medicines' as medicines with and without competition that cost more than 1,000 euros per patient per year.

Competition